JMP Securities Upgrades Achillion Pharmaceuticals to Outperform (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by analysts at JMP Securities from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Friday. The firm currently has a $13.00 price objective on the stock. JMP Securities’ price target would suggest a potential upside of 85.71% from the company’s current price.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 0.71% during mid-day trading on Friday, hitting $7.05. 293,081 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a one year low of $2.26 and a one year high of $8.61. The stock has a 50-day moving average of $7.26 and a 200-day moving average of $4.41. The company’s market cap is $682.4 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.77 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ACHN. Analysts at Wells Fargo & Co. raised their price target on shares of Achillion Pharmaceuticals to $8.00 in a research note on Monday, June 23rd. Separately, analysts at Maxim Group raised their price target on shares of Achillion Pharmaceuticals from $6.00 to $22.00 in a research note on Monday, June 16th. They now have a “buy” rating on the stock. Finally, analysts at Robert W. Baird upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $12.00 price target on the stock, up previously from $4.00. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $8.10.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.